首页> 外文OA文献 >Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial

【2h】

Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial

机译：使用响应适应涉及的位点放射治疗（Gazyvaro） - Gazai试验（Gazyvaro和课程放射治疗涉及 - 部位放射治疗）的临床型I / II在临床型I / II中的节点卵泡淋巴瘤（SHO级1/2）治疗单臂，非随机化，开放，国家，多中心第二阶段试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Laila König; Martin Dreyling; Jan Dürig; Marianne Engelhard; Karin Hohloch; Andreas Viardot; Mathias Witzens-Harig; Meinhard Kieser; Wolfram Klapper; Christiane Pott; Klaus Herfarth;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial [J] . Laila K?nig, Martin Dreyling, Jan Dürig, Trials . 2019,第1期

机译：使用响应适应涉及的位点放射治疗（Gazyvaro） - Gazai试验（Gazyvaro和课程放射治疗涉及 - 部位放射治疗）的临床型I / II在临床型I / II中的节点卵泡淋巴瘤（SHO级1/2）治疗单臂，非随机化，开放，国家，多中心第二阶段试验
2. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial [J] . Daniel Hofmann, Ulrike Nitz, Oleg Gluz, Trials . 2013,第1期

机译：WSG ADAPT –辅助动态标记物调整的个性化治疗试验，优化了早期乳腺癌的风险评估和治疗反应预测：一项针对前瞻性，多中心，受控，无盲，随机，研究者发起的II / III期研究方案
3. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome [J] . Adhikari Narayan, Biswas Ahitagni, Gogia Ajay, Journal of neuro-oncology. . 2018,第1期

机译：一种预期第二阶段试验响应适应全脑放射治疗后高剂量甲氨蝶呤化疗患者新诊断的原发性中枢神经系统淋巴瘤分析及早期临床结果
4. Optimal and Minimax Three-stage Designs for Phase II Clinical Trials Considering Response and Toxicity [C] . JIN Hua, YUAN Peng 2009 International Institute of Applied Statistics Studies(2009 国际应用统计学术研讨会）论文集 . 2009

机译：考虑反应和毒性的II期临床试验的最佳和Minimax三阶段设计
5. A phase II two stage clinical trial design to handle latent heterogeneity for a binary response. [D] . Barnes, Christopher Noel. 2010

机译：II期两阶段临床试验设计可处理二元反应的潜在异质性。
6. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm non-randomized open national multi-center phase II trial [O] . Laila König, Martin Dreyling, Jan Dürig, 2019

机译：使用适应性反应的介入位点放射疗法与奥比妥单抗（Gazyvaro）组合治疗在临床I / II期淋巴结滤泡性淋巴瘤（WHO 1/2级）-GAZAI试验（GAZyvaro和适应性反应的介入位点放射疗法）：一项针对单臂非随机开放国家多中心II期临床试验
7. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial [O] . 2013

机译：WSG ADAPT –辅助动态标记物调整的个性化治疗试验，优化了早期乳腺癌的风险评估和治疗反应预测：一项针对前瞻性，多中心，受控，无盲，随机，研究者发起的II / III期试验的研究方案

著录项

相似文献

相关主题

期刊订阅